Dr. Antoni Ribas is the director of the Tumor Immunology Program at the University of California, Los Angeles Comprehensive Cancer Center, and the chair of the Melanoma Committee at SWOG. Dr. Ribas specializes in the research and treatment of melanoma, the deadliest form of skin cancer. He is conducting several large clinical trials treating patients with immunotherapy―including the anti-PD-1 checkpoint inhibitor pembrolizumab and the oncolytic virus T-Vec―as well as targeted therapies. In recognition of his accomplishments, he has been elected to the American Society of Clinical Investigation and has received the 2018 AACR-CRI Lloyd J. Old Award in Cancer Immunology as well as the Richard and Hinda Rosenthal Memorial Award from the American Association for Cancer Research (AACR). In addition to being a member of CRI’s Clinical Leadership Committee, Dr. Ribas is a leader of the CRI-SU2C Dream Team.
If we can merge the high response rate and the elegance of targeted therapy with the durability of responses from immunotherapy, I feel we will make a big difference in treating cancer.
Let's spread the word about Immunotherapy! Click to share this page with your community.